来源:FC游戏站 更新:2020-11-17
用手机看
Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan''s website at A recorded replay of the presentation will be available for two weeks.
About Kosan
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade®) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin?). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan''s motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).
For additional information on Kosan Biosciences, please visit the company''s website at
Velcade? (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.
Herceptin? (trastuzumab) is a registered trademark of Genentech, Inc.
Source: Kosan Biosciences Incorporated